

# William M Pardridge

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3671308/publications.pdf>

Version: 2024-02-01

399  
papers

32,698  
citations

3149

92  
h-index

5519

163  
g-index

410  
all docs

410  
docs citations

410  
times ranked

20682  
citing authors

#	ARTICLE	IF	CITATIONS
1	The blood-brain barrier: Bottleneck in brain drug development. <i>NeuroRx</i> , 2005, 2, 3-14.	6.0	2,129
2	Drug Transport across the Blood-Brain Barrier. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1959-1972.	2.4	1,336
3	Blood-Brain Barrier delivery. <i>Drug Discovery Today</i> , 2007, 12, 54-61.	3.2	995
4	BLOOD-BRAIN BARRIER DRUG TARGETING: THE FUTURE OF BRAIN DRUG DEVELOPMENT. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2003, 3, 90-105.	3.4	586
5	TRANSPORT OF METABOLIC SUBSTRATES THROUGH THE BLOOD-BRAIN BARRIER. <i>Journal of Neurochemistry</i> , 1977, 28, 5-12.	2.1	523
6	Capillary Depletion Method for Quantification of Blood-Brain Barrier Transport of Circulating Peptides and Plasma Proteins. <i>Journal of Neurochemistry</i> , 1990, 54, 1882-1888.	2.1	443
7	Transport of Protein-Bound Hormones into Tissues <i>in Vivo</i> *. <i>Endocrine Reviews</i> , 1981, 2, 103-123.	8.9	438
8	Strategies to advance translational research into brain barriers. <i>Lancet Neurology</i> , The, 2008, 7, 84-96.	4.9	432
9	Drug Targeting to the Brain. <i>Pharmaceutical Research</i> , 2007, 24, 1733-1744.	1.7	421
10	Delivery of peptides and proteins through the blood-Brain barrier. <i>Advanced Drug Delivery Reviews</i> , 2001, 46, 247-279.	6.6	409
11	Drug and gene targeting to the brain with molecular trojan horses. <i>Nature Reviews Drug Discovery</i> , 2002, 1, 131-139.	21.5	405
12	Blood-brain barrier biology and methodology. <i>Journal of NeuroVirology</i> , 1999, 5, 556-569.	1.0	402
13	Transport of Steroid Hormones through the Rat Blood-Brain Barrier. <i>Journal of Clinical Investigation</i> , 1979, 64, 145-154.	3.9	382
14	CNS Drug Design Based on Principles of Blood-Brain Barrier Transport. <i>Journal of Neurochemistry</i> , 1998, 70, 1781-1792.	2.1	374
15	Drug and Gene Delivery to the Brain. <i>Neuron</i> , 2002, 36, 555-558.	3.8	369
16	Human Blood-Brain Barrier Insulin Receptor. <i>Journal of Neurochemistry</i> , 1985, 44, 1771-1778.	2.1	368
17	Blood-brain barrier transcytosis of insulin in developing rabbits. <i>Brain Research</i> , 1987, 420, 32-38.	1.1	361
18	CSF, blood-brain barrier, and brain drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 963-975.	2.4	356

#	ARTICLE	IF	CITATIONS
19	Intravenous RNA Interference Gene Therapy Targeting the Human Epidermal Growth Factor Receptor Prolongs Survival in Intracranial Brain Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 3667-3677.	3.2	317
20	Human blood-brain barrier transferrin receptor. <i>Metabolism: Clinical and Experimental</i> , 1987, 36, 892-895.	1.5	316
21	Receptor-Mediated Peptide Transport through the Blood-Brain Barrier*. <i>Endocrine Reviews</i> , 1986, 7, 314-330.	8.9	293
22	Kinetic analysis of blood-brain barrier transport of amino acids. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1975, 401, 128-136.	1.4	292
23	Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. <i>Pharmaceutical Research</i> , 1995, 12, 807-816.	1.7	277
24	KINETICS OF BLOOD-BRAIN BARRIER TRANSPORT OF PYRUVATE, LACTATE AND GLUCOSE IN SUCKLING, WEANLING AND ADULT RATS. <i>Journal of Neurochemistry</i> , 1979, 33, 439-445.	2.1	265
25	Drug Delivery to the Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1997, 17, 713-731.	2.4	262
26	Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. <i>Neurochemical Research</i> , 1998, 23, 635-644.	1.6	240
27	Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. <i>Journal of Neuroimmunology</i> , 2001, 114, 168-172.	1.1	240
28	Transport of small molecules through the blood-brain barrier: biology and methodology. <i>Advanced Drug Delivery Reviews</i> , 1995, 15, 5-36.	6.6	238
29	Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. <i>Journal of Neurochemistry</i> , 2002, 81, 203-206.	2.1	235
30	Kinetics of blood-brain barrier transport of hexoses. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1975, 382, 377-392.	1.4	234
31	Drug transport in brain via the cerebrospinal fluid. <i>Fluids and Barriers of the CNS</i> , 2011, 8, 7.	2.4	231
32	Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 373.	1.7	220
33	Synthesis of pegylated immunonanoparticles. <i>Pharmaceutical Research</i> , 2002, 19, 1137-1143.	1.7	206
34	Molecular Trojan horses for blood-brain barrier drug delivery. <i>Current Opinion in Pharmacology</i> , 2006, 6, 494-500.	1.7	205
35	Intravenous Nonviral Gene Therapy Causes Normalization of Striatal Tyrosine Hydroxylase and Reversal of Motor Impairment in Experimental Parkinsonism. <i>Human Gene Therapy</i> , 2003, 14, 1-12.	1.4	201
36	Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. <i>Biotechnology and Bioengineering</i> , 2007, 96, 381-391.	1.7	192

#	ARTICLE	IF	CITATIONS
37	4 Serum bioavailability of sex steroid hormones. <i>Clinics in Endocrinology and Metabolism</i> , 1986, 15, 259-278.	1.8	184
38	Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. <i>Pharmaceutical Research</i> , 2000, 17, 266-274.	1.7	181
39	Molecular Biology of the Blood-Brain Barrier. <i>Molecular Biotechnology</i> , 2005, 30, 057-070.	1.3	176
40	Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery. <i>Pharmaceutical Research</i> , 1994, 11, 738-746.	1.7	175
41	shRNA and siRNA delivery to the brain. <i>Advanced Drug Delivery Reviews</i> , 2007, 59, 141-152.	6.6	170
42	Neuroprotection in Transient Focal Brain Ischemia After Delayed Intravenous Administration of Brain-Derived Neurotrophic Factor Conjugated to a Blood-Brain Barrier Drug Targeting System. <i>Stroke</i> , 2001, 32, 1378-1384.	1.0	169
43	Global non-viral gene transfer to the primate brain following intravenous administration. <i>Molecular Therapy</i> , 2003, 7, 11-18.	3.7	168
44	Carrier-Mediated Transport of Thyroid Hormones through the Rat Blood-Brain Barrier: Primary Role of Albumin-Bound Hormone*. <i>Endocrinology</i> , 1979, 105, 605-612.	1.4	162
45	Biopharmaceutical drug targeting to the brain. <i>Journal of Drug Targeting</i> , 2010, 18, 157-167.	2.1	162
46	Re-Engineering Biopharmaceuticals for Delivery to Brain with Molecular Trojan Horses. <i>Bioconjugate Chemistry</i> , 2008, 19, 1327-1338.	1.8	160
47	Reengineering Biopharmaceuticals for Targeted Delivery Across the Blood-Brain Barrier. <i>Methods in Enzymology</i> , 2012, 503, 269-292.	0.4	159
48	Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. <i>Brain Research</i> , 2001, 889, 49-56.	1.1	158
49	Human blood-brain barrier insulin-like growth factor receptor. <i>Metabolism: Clinical and Experimental</i> , 1988, 37, 136-140.	1.5	155
50	Alzheimer's disease drug development and the problem of the blood-brain barrier. <i>Alzheimer's and Dementia</i> , 2009, 5, 427-432.	0.4	155
51	Transport of [125I]transferrin through the rat blood-brain barrier. <i>Brain Research</i> , 1995, 683, 164-171.	1.1	153
52	Blood-Brain Barrier Genomics. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 61-68.	2.4	150
53	Antisense Gene Therapy of Brain Cancer with an Artificial Virus Gene Delivery System. <i>Molecular Therapy</i> , 2002, 6, 67-72.	3.7	147
54	Blood-Brain Barrier: Interface Between Internal Medicine and the Brain. <i>Annals of Internal Medicine</i> , 1986, 105, 82.	2.0	146

#	ARTICLE	IF	CITATIONS
55	Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. <i>Pharmaceutical Research</i> , 2001, 18, 1091-1095.	1.7	144
56	Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion. <i>Brain Research</i> , 2006, 1111, 227-229.	1.1	141
57	Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. <i>Molecular Brain Research</i> , 1994, 27, 51-57.	2.5	136
58	Rapid transferrin efflux from brain to blood across the blood-brain barrier. <i>Journal of Neurochemistry</i> , 2001, 76, 1597-1600.	2.1	133
59	Vector-mediated drug delivery to the brain. <i>Advanced Drug Delivery Reviews</i> , 1999, 36, 299-321.	6.6	131
60	Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. <i>Biotechnology and Bioengineering</i> , 2009, 102, 1251-1258.	1.7	130
61	Why is the global CNS pharmaceutical market so under-penetrated?. <i>Drug Discovery Today</i> , 2002, 7, 5-7.	3.2	129
62	Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. <i>Biotechnology and Bioengineering</i> , 2008, 99, 475-484.	1.7	129
63	Palmitate and Cholesterol Transport Through the Blood-Brain Barrier. <i>Journal of Neurochemistry</i> , 1980, 34, 463-466.	2.1	128
64	Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration. <i>Pharmaceutical Research</i> , 1998, 15, 576-582.	1.7	128
65	Brain Microvascular and Astrocyte Localization of $\beta$ -Glycoprotein. <i>Journal of Neurochemistry</i> , 1997, 68, 1278-1285.	2.1	128
66	Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 207-222.	2.4	127
67	Receptor-mediated delivery of an antisense gene to human brain cancer cells. <i>Journal of Gene Medicine</i> , 2002, 4, 183-194.	1.4	125
68	Glucose Deprivation Causes Posttranscriptional Enhancement of Brain Capillary Endothelial Glucose Transporter Gene Expression via GLUT1 mRNA Stabilization. <i>Journal of Neurochemistry</i> , 1993, 60, 2290-2296.	2.1	124
69	Normalization of Striatal Tyrosine Hydroxylase and Reversal of Motor Impairment in Experimental Parkinsonism with Intravenous Nonviral Gene Therapy and a Brain-Specific Promoter. <i>Human Gene Therapy</i> , 2004, 15, 339-350.	1.4	124
70	Enhanced Neuroprotective Effects of Basic Fibroblast Growth Factor in Regional Brain Ischemia after Conjugation to a Blood-Brain Barrier Delivery Vector. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 301, 605-610.	1.3	123
71	Fusion Antibody for Alzheimer's Disease with Bidirectional Transport Across the Blood-Brain Barrier and $\text{A}\beta$ Fibril Disaggregation. <i>Bioconjugate Chemistry</i> , 2007, 18, 447-455.	1.8	121
72	Intravenous siRNA of Brain Cancer with Receptor Targeting and Avidin-Biotin Technology. <i>Pharmaceutical Research</i> , 2007, 24, 2309-2316.	1.7	121

#	ARTICLE	IF	CITATIONS
73	Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology. <i>BioDrugs</i> , 2017, 31, 503-519.	2.2	121
74	Rapid Sequestration and Degradation of Somatostatin Analogues by Isolated Brain Microvessels. <i>Journal of Neurochemistry</i> , 1985, 44, 1178-1184.	2.1	116
75	The brain-type glucose transporter mRNA is specifically expressed at the blood-brain barrier. <i>Biochemical and Biophysical Research Communications</i> , 1990, 166, 174-179.	1.0	116
76	In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. <i>Journal of Gene Medicine</i> , 2003, 5, 1039-1045.	1.4	116
77	Restricted Transport of Vitamin D and A Derivatives Through the Rat Blood-Brain Barrier. <i>Journal of Neurochemistry</i> , 1985, 44, 1138-1141.	2.1	114
78	Transport of Propranolol and Lidocaine through the Rat Blood-Brain Barrier. PRIMARY ROLE OF GLOBULIN-BOUND DRUG. <i>Journal of Clinical Investigation</i> , 1983, 71, 900-908.	3.9	111
79	Blood-brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1059-1072.	1.5	108
80	Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity. , 1997, 14, 1085-1091.		107
81	Intravenous, non-viral RNAi gene therapy of brain cancer. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 1103-1113.	1.4	107
82	Delivery of $\beta$ -Galactosidase to Mouse Brain via the Blood-Brain Barrier Transferrin Receptor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 1075-1081.	1.3	105
83	Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 110.	1.2	104
84	Kinetics of Transport and Phosphorylation of 2-Fluoro-2-Deoxy-d-Glucose in Rat Brain. <i>Journal of Neurochemistry</i> , 1983, 40, 160-167.	2.1	102
85	Blood-Brain Barrier Transport of Valproic Acid. <i>Journal of Neurochemistry</i> , 1985, 44, 1541-1550.	2.1	102
86	Transport of Albumin-bound Melatonin Through the Blood-Brain Barrier. <i>Journal of Neurochemistry</i> , 1980, 34, 1761-1763.	2.1	101
87	Pharmacokinetics and Brain Uptake of a Genetically Engineered Bifunctional Fusion Antibody Targeting the Mouse Transferrin Receptor. <i>Molecular Pharmaceutics</i> , 2010, 7, 237-244.	2.3	101
88	Enkephalin and Blood-Brain Barrier: Studies of Binding and Degradation in Isolated Brain Microvessels*. <i>Endocrinology</i> , 1981, 109, 1138-1143.	1.4	100
89	P-glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries. <i>Brain Research</i> , 1999, 819, 143-146.	1.1	100
90	The Interaction of Transport and Metabolism on Brain Glucose Utilization: A Reevaluation of the Lumped Constant. <i>Journal of Neurochemistry</i> , 1981, 36, 1601-1604.	2.1	99

#	ARTICLE	IF	CITATIONS
91	Kinetics of Regional Blood-Brain Barrier Transport and Brain Phosphorylation of Glucose and 2-Deoxyglucose in the Barbiturate-Anesthetized Rat. <i>Journal of Neurochemistry</i> , 1982, 38, 560-568.	2.1	99
92	Targeting Neurotherapeutic Agents Through the Blood-Brain Barrier. <i>Archives of Neurology</i> , 2002, 59, 35.	4.9	98
93	Targeted delivery of protein and gene medicines through the blood-brain barrier. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 347-361.	2.3	98
94	Restrictive Transport of a Lipid-Soluble Peptide (Cyclosporin) Through the Blood-Brain Barrier. <i>Journal of Neurochemistry</i> , 1985, 45, 1954-1956.	2.1	96
95	Treatment of Alzheimer's Disease and Blood-Brain Barrier Drug Delivery. <i>Pharmaceuticals</i> , 2020, 13, 394.	1.7	92
96	Gene therapy of the brain. <i>Neurology</i> , 2004, 62, 1275-1281.	1.5	91
97	The blood-brain barrier and neurotherapeutics. <i>NeuroRx</i> , 2005, 2, 1-2.	6.0	89
98	Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy. <i>NeuroRx</i> , 2005, 2, 129-138.	6.0	88
99	Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. <i>Journal of Biotechnology</i> , 2010, 146, 84-91.	1.9	88
100	Brain Protection from Stroke with Intravenous TNF Decoy Receptor-Trojan Horse Fusion Protein. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1933-1938.	2.4	88
101	Insulin receptor antibody-sulfatase fusion protein: Pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys. <i>Biotechnology and Bioengineering</i> , 2014, 111, 2317-2325.	1.7	88
102	Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter. <i>Journal of Gene Medicine</i> , 2008, 10, 306-315.	1.4	86
103	GDNF fusion protein for targeted drug delivery across the human blood-brain barrier. <i>Biotechnology and Bioengineering</i> , 2008, 100, 387-396.	1.7	86
104	Log(BB), PS products and in silico models of drug brain penetration. <i>Drug Discovery Today</i> , 2004, 9, 392-393.	3.2	85
105	Blood-Brain Barrier Transport of Butanol and Water Relative to <i>N</i> -Isopropyl- <i>p</i> -Iodoamphetamine as the Internal Reference. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1985, 5, 275-281.	2.4	84
106	Pharmacokinetics and Delivery of Tat and Tat-Protein Conjugates to Tissues in Vivo. <i>Bioconjugate Chemistry</i> , 2001, 12, 995-999.	1.8	84
107	hnRNP A2 and hnRNP L Bind the 3'UTR of Glucose Transporter 1 mRNA and Exist as a Complex in Vivo. <i>Biochemical and Biophysical Research Communications</i> , 1999, 261, 646-651.	1.0	83
108	Up-Regulation of Blood-Brain Barrier Short-Form Leptin Receptor Gene Products in Rats Fed a High Fat Diet. <i>Journal of Neurochemistry</i> , 2002, 71, 1761-1764.	2.1	81

#	ARTICLE	IF	CITATIONS
109	Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. <i>Biotechnology and Bioengineering</i> , 2007, 97, 1376-1386.	1.7	80
110	Influx of Thyroid Hormones into Rat Liver In Vivo. <i>Journal of Clinical Investigation</i> , 1980, 66, 367-374.	3.9	80
111	Drug Targeting of Erythropoietin Across the Primate Blood-Brain Barrier with an IgG Molecular Trojan Horse. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 333, 961-969.	1.3	79
112	Immunohistochemical study of cerebral amyloid angiopathy. III. Widespread alzheimer A4 peptide in cerebral microvessel walls colocalizes with gamma trace in patients with leukoencephalopathy. <i>Annals of Neurology</i> , 1990, 28, 34-42.	2.8	78
113	Blood-brain barrier transport of reduced folic acid. <i>Pharmaceutical Research</i> , 1999, 16, 415-419.	1.7	78
114	Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses. <i>Journal of Controlled Release</i> , 2007, 122, 345-348.	4.8	78
115	Imaging Brain Amyloid of Alzheimer Disease in Vivo in Transgenic Mice with an A $\beta$ Peptide Radiopharmaceutical. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002, 22, 223-231.	2.4	77
116	Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier. <i>Biochemical and Biophysical Research Communications</i> , 1987, 146, 307-313.	1.0	76
117	Transport of Tryptophan into Brain from the Circulating, Albumin-Bound Pool in Rats and in Rabbits. <i>Journal of Neurochemistry</i> , 1990, 54, 971-976.	2.1	75
118	Molecular cloning of the bovine blood-brain barrier glucose transporter cDNA and demonstration of phylogenetic conservation of the 5'-untranslated region. <i>Molecular and Cellular Neurosciences</i> , 1990, 1, 224-232.	1.0	75
119	Enhanced cellular uptake of biotinylated antisense oligonucleotide or peptide mediated by avidin, a cationic protein. <i>FEBS Letters</i> , 1991, 288, 30-32.	1.3	75
120	Blood-Brain Barrier Penetrating Biologic TNF-Inhibitor for Alzheimer's Disease. <i>Molecular Pharmaceutics</i> , 2017, 14, 2340-2349.	2.3	75
121	Cloned Blood-Brain Barrier Adenosine Transporter is Identical to the Rat Concentrative Na <sup>+</sup> Nucleoside Cotransporter CNT2. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 929-936.	2.4	74
122	Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer. <i>Molecular Vision</i> , 2003, 9, 465-72.	1.1	73
123	Astrocyte Growth Stimulation by a Soluble Factor Produced by Cerebral Endothelial Cells in vitro. <i>Journal of Neuropathology and Experimental Neurology</i> , 1990, 49, 539-549.	0.9	72
124	Monoclonal Antibody Radiopharmaceuticals: Cationization, Pegylation, Radiometal Chelation, Pharmacokinetics, and Tumor Imaging. <i>Bioconjugate Chemistry</i> , 2003, 14, 546-553.	1.8	72
125	Crossing the blood-brain barrier: are we getting it right?. <i>Drug Discovery Today</i> , 2001, 6, 1-2.	3.2	71
126	Amyloid Angiopathy of Alzheimer's Disease: Amino Acid Composition and Partial Sequence of a 4,200-Dalton Peptide Isolated from Cortical Microvessels. <i>Journal of Neurochemistry</i> , 1987, 49, 1394-1401.	2.1	70



#	ARTICLE	IF	CITATIONS
127	$\beta$ -Endorphin Chimeric Peptides: Transport through the Blood-Brain Barrier <i>in Vivo</i> and Cleavage of Bisulfide Linkage by Brain*. <i>Endocrinology</i> , 1990, 126, 977-984.	1.4	70
128	Carotid Artery Injection Technique: Bounds for Bolus Mixing by Plasma and by Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1985, 5, 576-583.	2.4	69
129	Transport of Insulin-Related Peptides and Glucose across the Blood-Brain Barrier. <i>Annals of the New York Academy of Sciences</i> , 1993, 692, 126-137.	1.8	69
130	Epidermal Growth Factor Radiopharmaceuticals: $^{111}\text{In}$ Chelation, Conjugation to a Blood-Brain Barrier Delivery Vector via a Biotin-Polyethylene Linker, Pharmacokinetics, and <i>in Vivo</i> Imaging of Experimental Brain Tumors. <i>Bioconjugate Chemistry</i> , 1999, 10, 502-511.	1.8	69
131	Brain microvascular P-glycoprotein and a revised model of multidrug resistance in brain. <i>Cellular and Molecular Neurobiology</i> , 2000, 20, 165-181.	1.7	69
132	Blood-Brain Barrier Protein and Phosphorylation and Dephosphorylation. <i>Journal of Neurochemistry</i> , 1985, 45, 1141-1147.	2.1	68
133	A One-Step Procedure for Isolation of Poly(A) <sup>+</sup> mRNA from Isolated Brain Capillaries and Endothelial Cells in Culture. <i>Journal of Neurochemistry</i> , 1991, 57, 2136-2139.	2.1	68
134	Glucose deprivation and hypoxia increase the expression of the GLUT1 glucose transporter via a specific mRNA cis-acting regulatory element. <i>Journal of Neurochemistry</i> , 2002, 80, 552-554.	2.1	68
135	Examination of Blood-Brain Barrier Transferrin Receptor by Confocal Fluorescent Microscopy of Unfixed Isolated Rat Brain Capillaries. <i>Journal of Neurochemistry</i> , 1998, 70, 883-886.	2.1	68
136	Enhanced Hepatic Extraction of Estrogens Used for Replacement Therapy*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1986, 62, 761-766.	1.8	67
137	Pathological upregulation of inner blood-retinal barrier Glut1 glucose transporter expression in diabetes mellitus. <i>Brain Research</i> , 1996, 706, 313-317.	1.1	67
138	Non-invasive drug delivery to the human brain using endogenous blood-brain barrier transport systems. <i>Pharmaceutical Science &amp; Technology Today</i> , 1999, 2, 49-59.	0.7	67
139	Reversal of Lysosomal Storage in Brain of Adult MPS-I Mice with Intravenous Trojan Horse-Iduronidase Fusion Protein. <i>Molecular Pharmaceutics</i> , 2011, 8, 1342-1350.	2.3	67
140	An Electron Microscopic Immunogold Analysis of Developmental Up-Regulation of the Blood-Brain Barrier GLUT1 Glucose Transporter. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1993, 13, 841-854.	2.4	66
141	The Trojan Horse Liposome Technology for Nonviral Gene Transfer across the Blood-Brain Barrier. <i>Journal of Drug Delivery</i> , 2011, 2011, 1-12.	2.5	65
142	A Historical Review of Brain Drug Delivery. <i>Pharmaceutics</i> , 2022, 14, 1283.	2.0	65
143	BBB-Genomics: creating new openings for brain-drug targeting. <i>Drug Discovery Today</i> , 2001, 6, 381-383.	3.2	64
144	Near Complete Rescue of Experimental Parkinson's Disease with Intravenous, Non-viral GDNF Gene Therapy. <i>Pharmaceutical Research</i> , 2009, 26, 1059-1063.	1.7	64

#	ARTICLE	IF	CITATIONS
145	Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody-Iduronidase Fusion Protein. <i>Molecular Pharmaceutics</i> , 2017, 14, 1271-1277.	2.3	64
146	Kinetics of Neutral Amino Acid Transport Through the Blood-Brain Barrier of the Newborn Rabbit. <i>Journal of Neurochemistry</i> , 1982, 38, 955-962.	2.1	63
147	Blood-brain barrier transport of 125I-labeled basic fibroblast growth factor. <i>Pharmaceutical Research</i> , 2000, 17, 63-69.	1.7	62
148	Nomogram for 2-Deoxyglucose Lumped Constant for Rat Brain Cortex. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1982, 2, 197-202.	2.4	61
149	Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS. <i>Journal of Pharmaceutical Sciences</i> , 1998, 87, 1308-1315.	1.6	61
150	P-glycoprotein and caveolin-1 in endothelium and astrocytes of primate brain. <i>NeuroReport</i> , 2003, 14, 2041-2046.	0.6	61
151	Antibody-Mediated Targeting of siRNA via the Human Insulin Receptor Using Avidin-Biotin Technology. <i>Molecular Pharmaceutics</i> , 2009, 6, 747-751.	2.3	61
152	Comparison of Blood-Brain Barrier Transport of Glial-Derived Neurotrophic Factor (GDNF) and an IgG-GDNF Fusion Protein in the Rhesus Monkey. <i>Drug Metabolism and Disposition</i> , 2009, 37, 2299-2304.	1.7	60
153	Blood-Brain Barrier Drug Targeting Enables Neuroprotection in Brain Ischemia Following Delayed Intravenous Administration of Neurotrophins. <i>Advances in Experimental Medicine and Biology</i> , 2003, 513, 397-430.	0.8	60
154	Blood-Brain Barrier Molecular Trojan Horse Enables Imaging of Brain Uptake of Radioiodinated Recombinant Protein in the Rhesus Monkey. <i>Bioconjugate Chemistry</i> , 2013, 24, 1741-1749.	1.8	59
155	Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor. <i>Biotechnology and Bioengineering</i> , 2013, 110, 1456-1465.	1.7	59
156	Vascular Genomics of the Human Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002, 22, 245-252.	2.4	58
157	Insulin Receptor Antibody-Sulfamidase Fusion Protein Penetrates the Primate Blood-Brain Barrier and Reduces Glycosaminoglycans in Sanfilippo Type A Cells. <i>Molecular Pharmaceutics</i> , 2014, 11, 2928-2934.	2.3	58
158	Influx of Testosterone-Binding Globulin (TeBG) and TeBG-Bound Sex Steroid Hormones Into Rat Testis and Prostate*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1988, 67, 98-103.	1.8	57
159	Recent Developments in Peptide Drug Delivery to the Brain. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1992, 71, 3-10.	0.0	57
160	Absence of Toxicity of Chronic Weekly Intravenous Gene Therapy with Pegylated Immunoliposomes. <i>Pharmaceutical Research</i> , 2003, 20, 1779-1785.	1.7	57
161	Neuroprotection with a Brain-Penetrating Biologic Tumor Necrosis Factor Inhibitor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 339, 618-623.	1.3	57
162	Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier. <i>Brain Research</i> , 2010, 1352, 208-213.	1.1	56

#	ARTICLE	IF	CITATIONS
163	Blood-brain barrier glucose transporter mRNA is increased in experimental diabetes mellitus. <i>Biochemical and Biophysical Research Communications</i> , 1989, 164, 375-380.	1.0	55
164	Ten nucleotide cis element in the 3' untranslated region of the GLUT1 glucose transporter mRNA increases gene expression via mRNA stabilization. <i>Molecular Brain Research</i> , 1998, 59, 109-113.	2.5	55
165	Antibodies to Blood-Brain Barrier Bind Selectively to Brain Capillary Endothelial Lateral Membranes and to a 46K Protein. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1986, 6, 203-211.	2.4	53
166	Determination of in vivo steady-state unbound drug concentration in the brain interstitial fluid by microdialysis. <i>International Journal of Pharmaceutics</i> , 1992, 81, 143-152.	2.6	51
167	Brain Drug Targeting and Gene Technologies. <i>The Japanese Journal of Pharmacology</i> , 2001, 87, 97-103.	1.2	51
168	Pharmacokinetics and Brain Uptake of Biotinylated Basic Fibroblast Growth Factor Conjugated to a Blood-Brain Barrier Drug Delivery System. <i>Journal of Drug Targeting</i> , 2002, 10, 239-245.	2.1	51
169	Differential glycosylation of the GLUT1 glucose transporter in brain capillaries and choroid plexus. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1994, 1193, 24-30.	1.4	50
170	Subtractive Expression Cloning Reveals High Expression of CD46 at the Blood-Brain Barrier. <i>Journal of Neuropathology and Experimental Neurology</i> , 2002, 61, 597-604.	0.9	50
171	Brain Drug Development and Brain Drug Targeting. <i>Pharmaceutical Research</i> , 2007, 24, 1729-1732.	1.7	50
172	Lysosomal Enzyme Replacement of the Brain with Intravenous Non-Viral Gene Transfer. <i>Pharmaceutical Research</i> , 2008, 25, 400-406.	1.7	50
173	ACT-181: Expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. <i>Journal of Biotechnology</i> , 2009, 144, 135-141.	1.9	50
174	Low blood-brain barrier permeability to azidothymidine (AZT), 3TC, and thymidine in the rat. <i>Brain Research</i> , 1998, 791, 313-316.	1.1	49
175	Disaggregation of Amyloid Plaque in Brain of Alzheimer's Disease Transgenic Mice with Daily Subcutaneous Administration of a Tetravalent Bispecific Antibody That Targets the Transferrin Receptor and the Abeta Amyloid Peptide. <i>Molecular Pharmaceutics</i> , 2013, 10, 3507-3513.	2.3	49
176	Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1455-1468.	1.4	49
177	Enhanced cellular uptake and in vivo biodistribution of a monoclonal antibody following cationization. <i>Journal of Pharmaceutical Sciences</i> , 1995, 84, 943-948.	1.6	48
178	<sup>125</sup> I-40Peptide Radiopharmaceuticals for Brain Amyloid Imaging: <sup>111</sup> In Chelation, Conjugation to Poly(ethylene glycol)-Biotin Linkers, and Autoradiography with Alzheimer's Disease Brain Sections. <i>Bioconjugate Chemistry</i> , 2000, 11, 380-386.	1.8	48
179	Marked enhancement in gene expression by targeting the human insulin receptor. <i>Journal of Gene Medicine</i> , 2003, 5, 157-163.	1.4	48
180	Selective Delivery of Sex Steroid Hormones to Tissues In Vivo by Albumin and by Sex Hormone-Binding Globulin. <i>Annals of the New York Academy of Sciences</i> , 1988, 538, 173-192.	1.8	47

#	ARTICLE	IF	CITATIONS
181	BLOOD-BRAIN BARRIER TRANSPORT OF NUTRIENTS. <i>Nutrition Reviews</i> , 2009, 44, 15-25.	2.6	47
182	Imaging endogenous gene expression in brain cancer in vivo with <sup>111</sup> In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1766-75.	2.8	47
183	In Vivo Cleavability of a Disulfide-Based Chimeric Opioid Peptide in Rat Brain. <i>Bioconjugate Chemistry</i> , 1995, 6, 211-218.	1.8	46
184	Gene Targeting In Vivo with Pegylated Immunoliposomes. <i>Methods in Enzymology</i> , 2003, 373, 507-528.	0.4	46
185	Glycemic Control and Chronic Dosing of Rhesus Monkeys with a Fusion Protein of Iduronidase and a Monoclonal Antibody Against the Human Insulin Receptor. <i>Drug Metabolism and Disposition</i> , 2012, 40, 2021-2025.	1.7	46
186	Blood-Brain Barrier Transport, Plasma Pharmacokinetics, and Neuropathology Following Chronic Treatment of the Rhesus Monkey with a Brain Penetrating Humanized Monoclonal Antibody Against the Human Transferrin Receptor. <i>Molecular Pharmaceutics</i> , 2018, 15, 5207-5216.	2.3	46
187	Enhanced expression of the blood-brain barrier GLUT1 glucose transporter gene by brain-derived factors. <i>Molecular Brain Research</i> , 1994, 22, 259-267.	2.5	45
188	Drug and gene targeting to the brain via blood-brain barrier receptor-mediated transport systems. <i>International Congress Series</i> , 2005, 1277, 49-62.	0.2	45
189	Pharmacokinetics and Safety in Rhesus Monkeys of a Monoclonal Antibody-GDNF Fusion Protein for Targeted Blood-Brain Barrier Delivery. <i>Pharmaceutical Research</i> , 2009, 26, 2227-2236.	1.7	45
190	Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington's disease with an antisense radiopharmaceutical and drug-targeting technology. <i>Journal of Nuclear Medicine</i> , 2002, 43, 948-56.	2.8	45
191	Kinetics of Regional Blood-Brain Barrier Glucose Transport and Cerebral Blood Flow Determined with the Carotid Injection Technique in Conscious Rats. <i>Journal of Neurochemistry</i> , 1985, 44, 911-915.	2.1	44
192	Molecular Trojan horses for blood-brain barrier drug delivery. <i>Discovery Medicine</i> , 2006, 6, 139-43.	0.5	43
193	Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease. <i>Molecular Pharmaceutics</i> , 2018, 15, 4963-4973.	2.3	42
194	Immunohistochemical study of cerebral amyloid angiopathy: Use of an antiserum to a synthetic 28-amino-acid peptide fragment of the Alzheimer's disease amyloid precursor. <i>Human Pathology</i> , 1988, 19, 214-222.	1.1	41
195	Vector-mediated peptide drug delivery to the brain. <i>Advanced Drug Delivery Reviews</i> , 1995, 15, 109-146.	6.6	41
196	Retention of Biologic Activity of Human Epidermal Growth Factor Following Conjugation to a Blood-Brain Barrier Drug Delivery Vector via an Extended Poly(ethylene glycol) Linker. <i>Bioconjugate Chemistry</i> , 1999, 10, 32-37.	1.8	41
197	Cis-Element/Cytoplasmic Protein Interaction Within the 5' Untranslated Region of the GLUT1 Glucose Transporter mRNA. <i>Journal of Neurochemistry</i> , 1996, 66, 449-458.	2.1	41
198	Monoclonal Antibody-Glial-Derived Neurotrophic Factor Fusion Protein Penetrates the Blood-Brain Barrier in the Mouse. <i>Drug Metabolism and Disposition</i> , 2010, 38, 566-572.	1.7	41

#	ARTICLE	IF	CITATIONS
199	Receptor-Mediated Abeta Amyloid Antibody Targeting to Alzheimer's Disease Mouse Brain. <i>Molecular Pharmaceutics</i> , 2011, 8, 280-285.	2.3	41
200	Brain delivery of biotin bound to a conjugate of neutral avidin and cationized human albumin. <i>Pharmaceutical Research</i> , 1994, 11, 1257-1264.	1.7	40
201	Blood-Brain Barrier Genomics. <i>Stroke</i> , 2007, 38, 686-690.	1.0	40
202	Chronic Dosing of Mice with a Transferrin Receptor Monoclonal Antibody-Glial-Derived Neurotrophic Factor Fusion Protein. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1149-1154.	1.7	40
203	Brain-Penetrating IgG-Iduronate 2-Sulfatase Fusion Protein for the Mouse. <i>Drug Metabolism and Disposition</i> , 2012, 40, 329-335.	1.7	40
204	Protein-Bound Corticosteroid in Human Serum Is Selectively Transported into Rat Brain and Liver in Vivo*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1983, 57, 160-165.	1.8	39
205	Pharmacokinetics of [3H]Biotin Bound to Different Avidin Analogues. <i>Journal of Drug Targeting</i> , 1995, 3, 159-165.	2.1	39
206	Pharmacokinetics and Brain Uptake of an IgG-TNF Decoy Receptor Fusion Protein Following Intravenous, Intraperitoneal, and Subcutaneous Administration in Mice. <i>Molecular Pharmaceutics</i> , 2013, 10, 1425-1431.	2.3	39
207	Blood-Brain Barrier Genomics and Cloning of a Novel Organic Anion Transporter. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008, 28, 291-301.	2.4	38
208	Genetic Engineering, Expression, and Activity of a Chimeric Monoclonal Antibody-Avidin Fusion Protein for Receptor-Mediated Delivery of Biotinylated Drugs in Humans. <i>Bioconjugate Chemistry</i> , 2008, 19, 731-739.	1.8	38
209	IgG-single chain Fv fusion protein therapeutic for alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey. <i>Biotechnology and Bioengineering</i> , 2010, 105, 627-635.	1.7	38
210	Insulin Receptor Antibody-N-Acetylglucosaminidase Fusion Protein Penetrates the Primate Blood-Brain Barrier and Reduces Glycosaminoglycans in Sanfilippo Type B Fibroblasts. <i>Molecular Pharmaceutics</i> , 2016, 13, 1385-1392.	2.3	38
211	Delivery of peptides and proteins through the blood-brain barrier. <i>Advanced Drug Delivery Reviews</i> , 1993, 10, 205-245.	6.6	37
212	Genetic Engineering of a Bifunctional IgG Fusion Protein with Iduronate-2-Sulfatase. <i>Bioconjugate Chemistry</i> , 2010, 21, 151-156.	1.8	37
213	Brain-Penetrating Tumor Necrosis Factor Decoy Receptor in the Mouse. <i>Drug Metabolism and Disposition</i> , 2011, 39, 71-76.	1.7	36
214	New approaches to drug delivery through the blood-brain barrier. <i>Trends in Biotechnology</i> , 1994, 12, 239-245.	4.9	35
215	Enzymatic barrier protects brain capillaries from leukotriene C4. <i>Journal of Neurosurgery</i> , 1994, 81, 745-751.	0.9	35
216	Blood-brain barrier amino acid transport. , 1998, , 188-197.		35

#	ARTICLE	IF	CITATIONS
217	Re-Engineering Erythropoietin as an IgG Fusion Protein That Penetrates the Blood-Brain Barrier in the Mouse. <i>Molecular Pharmaceutics</i> , 2010, 7, 2148-2155.	2.3	35
218	Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse. <i>Brain Research</i> , 2011, 1382, 315-320.	1.1	35
219	Neurotrophins, neuroprotection and the blood-brain barrier. <i>Current Opinion in Investigational Drugs</i> , 2002, 3, 1753-7.	2.3	35
220	Brain Capillary 46,000 Dalton Protein is Cytoplasmic Actin and is Localized to Endothelial Plasma Membrane. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1989, 9, 675-680.	2.4	34
221	Rat Blood-Brain Barrier Genomics. II. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002, 22, 1319-1326.	2.4	34
222	Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-Iduronate-2-sulfatase fusion protein. <i>Biotechnology and Bioengineering</i> , 2011, 108, 1954-1964.	1.7	34
223	Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I. <i>BioDrugs</i> , 2018, 32, 169-176.	2.2	34
224	Complete protection of antisense oligonucleotides against serum nuclease degradation by an avidin-biotin system. <i>Bioconjugate Chemistry</i> , 1992, 3, 519-523.	1.8	33
225	Blood-Brain Barrier Disruption Following the Internal Carotid Arterial Perfusion of Alkyl Glycerols. <i>Journal of Drug Targeting</i> , 2002, 10, 463-467.	2.1	32
226	Transport of Thyroid and Steroid Hormones through the Blood-Brain Barrier of the Newborn Rabbit: Primary Role of Protein-Bound Hormone*. <i>Endocrinology</i> , 1980, 107, 1705-1710.	1.4	31
227	The Effect of Membrane Permeability and Binding by Human Serum Proteins on Sex Steroid Influx into the Uterus*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1983, 56, 1282-1287.	1.8	31
228	Two-Day Starvation Does Not Alter the Kinetics of Blood-Brain Barrier Transport and Phosphorylation of Glucose in Rat Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1985, 5, 40-46.	2.4	31
229	Serum Bioavailability and Tissue Metabolism of Testosterone and Estradiol in Rat Salivary Gland*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1986, 63, 20-28.	1.8	31
230	Brain drug delivery and blood-brain barrier transport. <i>Drug Delivery</i> , 1993, 1, 83-101.	2.5	31
231	Development and in vitro Characterization of a Cationized Monoclonal Antibody against $\beta$ A4 Protein: A Potential Probe for Alzheimer's Disease. <i>Bioconjugate Chemistry</i> , 1994, 5, 119-125.	1.8	31
232	Genetic engineering of IgG-glucuronidase fusion proteins. <i>Journal of Drug Targeting</i> , 2010, 18, 205-211.	2.1	31
233	Neuroprotection in stroke in the mouse with intravenous erythropoietin-Trojan horse fusion protein. <i>Brain Research</i> , 2011, 1369, 203-207.	1.1	31
234	Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse. <i>Molecular Pharmaceutics</i> , 2018, 15, 602-608.	2.3	31

#	ARTICLE	IF	CITATIONS
235	The Isolated Brain Microvessel: A Versatile Experimental Model of the Blood-Brain Barrier. <i>Frontiers in Physiology</i> , 2020, 11, 398.	1.3	31
236	Complete Inactivation of Target mRNA by Biotinylated Antisense Oligodeoxynucleotide-Avidin Conjugates. <i>Bioconjugate Chemistry</i> , 1994, 5, 406-410.	1.8	30
237	Organ-specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice. <i>Journal of Gene Medicine</i> , 2004, 6, 906-912.	1.4	30
238	Measurement of Blood-Brain Barrier GLUT1 Glucose Transporter and Actin mRNA by a Quantitative Polymerase Chain Reaction Assay. <i>Journal of Neurochemistry</i> , 1994, 62, 2085-2090.	2.1	30
239	Biologic TNF $\pm$ -inhibitors that cross the human blood-brain barrier. <i>Bioengineered Bugs</i> , 2010, 1, 233-236.	2.0	30
240	IgG-Enzyme Fusion Protein: Pharmacokinetics and Anti-Drug Antibody Response in Rhesus Monkeys. <i>Bioconjugate Chemistry</i> , 2013, 24, 97-104.	1.8	30
241	Widespread expression of an exogenous gene in the eye after intravenous administration. <i>Investigative Ophthalmology and Visual Science</i> , 2002, 43, 3075-80.	3.3	30
242	High molecular weight Alzheimer's disease amyloid peptide immunoreactivity in human serum and CSF is an immunoglobulin G. <i>Biochemical and Biophysical Research Communications</i> , 1987, 145, 241-248.	1.0	29
243	Insulin therapy normalizes GLUT1 glucose transporter mRNA but not immunoreactive transporter protein in streptozocin-diabetic rats. <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 939-944.	1.5	29
244	Cationization of a monoclonal antibody to the human immunodeficiency virus REV protein enhances cellular uptake but does not impair antigen binding of the antibody. <i>Immunology Letters</i> , 1994, 42, 191-195.	1.1	29
245	Hypoxia induces de $\alpha$ -stabilization of the LAT1 large neutral amino acid transporter mRNA in brain capillary endothelial cells. <i>Journal of Neurochemistry</i> , 2003, 85, 1037-1042.	2.1	29
246	Preparation of Trojan Horse Liposomes (THLs) for Gene Transfer across the Blood-Brain Barrier. <i>Cold Spring Harbor Protocols</i> , 2010, 2010, pdb.prot5407.	0.2	29
247	Increased Blood-Brain Barrier Transport of Protein-Bound Anticonvulsant Drugs in the Newborn. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1983, 3, 280-286.	2.4	28
248	Vascular Proteomics and Subtractive Antibody Expression Cloning. <i>Molecular and Cellular Proteomics</i> , 2002, 1, 75-82.	2.5	28
249	Delivery of a Peptide Radiopharmaceutical to Brain with an IgG-Avidin Fusion Protein. <i>Bioconjugate Chemistry</i> , 2011, 22, 1611-1618.	1.8	28
250	Combination stroke therapy in the mouse with blood-brain barrier penetrating IgG $\alpha$ -GDNF and IgG $\alpha$ -TNF decoy receptor fusion proteins. <i>Brain Research</i> , 2013, 1507, 91-96.	1.1	28
251	Site-directed mutagenesis of cysteine residues of large neutral amino acid transporter LAT1. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2005, 1715, 104-110.	1.4	27
252	Mechanisms of Neuropeptide Interaction with the Blood-Brain Barrier. <i>Annals of the New York Academy of Sciences</i> , 1986, 481, 231-249.	1.8	26

#	ARTICLE	IF	CITATIONS
253	Evidence for Translational Control Elements Within the 5'â€²-Untranslated Region of GLUT1 Glucose Transporter mRNA. <i>Journal of Neurochemistry</i> , 2002, 67, 1335-1343.	2.1	26
254	Tumor Necrosis Factor Receptor-IgG Fusion Protein for Targeted Drug Delivery across the Human Bloodâ€²Brain Barrier. <i>Molecular Pharmaceutics</i> , 2009, 6, 1536-1543.	2.3	26
255	Blood-Brain Barrier Transport of Glucose, Free Fatty Acids, and Ketone Bodies. <i>Advances in Experimental Medicine and Biology</i> , 1991, 291, 43-53.	0.8	26
256	Inorganic mercury: selective effects on blood-brain barrier transport systems. <i>Journal of Neurochemistry</i> , 1976, 27, 333-335.	2.1	25
257	Measurement of Cerebral Glucose Utilization Using Washout After Carotid Injection in the Rat. <i>Journal of Neurochemistry</i> , 1982, 38, 1413-1418.	2.1	25
258	Critical Illness and Low Testosterone: Effects of Human Serum on Testosterone Transport into Rat Brain and Liver*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1983, 56, 710-714.	1.8	25
259	Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies. <i>Journal of Drug Targeting</i> , 2012, 20, 715-719.	2.1	25
260	Glucose transport and phosphorylation: Which is rate limiting for brain glucose utilization?. <i>Annals of Neurology</i> , 1994, 35, 511-512.	2.8	24
261	Brain drug delivery and bloodâ€²brain barrier transport. <i>Drug Delivery</i> , 1996, 3, 99-115.	2.5	24
262	Molecular Biology of the Bloodâ€²Brain Barrier. , 2003, 89, 385-400.		24
263	Mathematical Models of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Transferrin Receptor and the Insulin Receptor. <i>Pharmaceutics</i> , 2021, 14, 535.	1.7	24
264	Glucose and amino acid metabolism in an established line of skeletal muscle cells. <i>Journal of Cellular Physiology</i> , 1978, 96, 309-317.	2.0	23
265	The Blood-Brain Barrier in Alzheimer's Disease. <i>Canadian Journal of Neurological Sciences</i> , 1986, 13, 446-448.	0.3	22
266	Measurement of Free Intracellular and Transfer RNA Amino Acid Specific Activity and Protein Synthesis in Rat Brain in vivo. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1990, 10, 162-169.	2.4	22
267	Decline in Exogenous Gene Expression in Primate Brain Following Intravenous Administration Is Due to Plasmid Degradation. <i>Pharmaceutical Research</i> , 2006, 23, 1586-1590.	1.7	22
268	IgG-Paraoxonase-1 Fusion Protein for Targeted Drug Delivery across the Human Bloodâ€²Brain Barrier. <i>Molecular Pharmaceutics</i> , 2008, 5, 1037-1043.	2.3	22
269	Plasmid DNA gene therapy of the Niemann-Pick C1 mouse with transferrin receptor-targeted Trojan horse liposomes. <i>Scientific Reports</i> , 2020, 10, 13334.	1.6	22
270	Chapter 31. Strategies for Delivery of Drugs Through the Blood-Brain Barrier. <i>Annual Reports in Medicinal Chemistry</i> , 1985, 20, 305-313.	0.5	21



#	ARTICLE	IF	CITATIONS
271	GLUT1 glucose transporter: differential gene transcription and mRNA binding to cytosolic and polysome proteins in brain and peripheral tissues. <i>Molecular Brain Research</i> , 1998, 58, 170-177.	2.5	21
272	The Ro52/SS-A autoantigen has elevated expression at the brain microvasculature. <i>NeuroReport</i> , 2003, 14, 1861-1865.	0.6	21
273	Comparison of cDNA and genomic forms of tyrosine hydroxylase gene therapy of the brain with Trojan horse liposomes. <i>Journal of Gene Medicine</i> , 2007, 9, 605-612.	1.4	21
274	Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins. <i>Advanced Drug Delivery Reviews</i> , 2022, 184, 114234.	6.6	21
275	Site-directed mutagenesis of rabbit LAT1 at amino acids 219 and 234. <i>Journal of Neurochemistry</i> , 2003, 84, 1322-1331.	2.1	20
276	Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain. <i>Frontiers in Medical Technology</i> , 2020, 2, 602236.	1.3	20
277	Kinetics of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Insulin Receptor and the Transferrin Receptor. <i>Pharmaceuticals</i> , 2022, 15, 3.	1.7	20
278	Enhanced GLUT1 glucose transporter and cytoskeleton gene expression in cultured bovine brain capillary endothelial cells after treatment with phorbol esters and serum. <i>Molecular Brain Research</i> , 1992, 15, 221-226.	2.5	19
279	Drug delivery of antisense oligonucleotides or peptides to tissues <i>in vivo</i> using an avidin-biotin system. <i>Drug Delivery</i> , 1993, 1, 43-50.	2.5	19
280	Neuroprotection in experimental stroke in the rat with an IgG-erythropoietin fusion protein. <i>Brain Research</i> , 2010, 1360, 193-197.	1.1	19
281	Alzheimer's disease: future drug development and the blood-brain barrier. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 569-572.	1.9	19
282	Regional blood-brain barrier transport of the steroid hormones. <i>Journal of Neurochemistry</i> , 1979, 33, 579-581.	2.1	18
283	Does the brain's gatekeeper falter in aging?. <i>Neurobiology of Aging</i> , 1988, 9, 44-46.	1.5	18
284	Differential expression of 53- and 45-kDa brain capillary-specific proteins by brain capillary endothelium and choroid plexus <i>in vivo</i> and by brain capillary endothelium in tissue culture. <i>Molecular and Cellular Neurosciences</i> , 1990, 1, 20-28.	1.0	18
285	Drug Targeting to the Brain Using Avidin-Biotin Technology in the Mouse (Blood-Brain Barrier.) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 107</i> 413-424.	2.1	18
286	Bi-functional IgG-lysosomal enzyme fusion proteins for brain drug delivery. <i>Scientific Reports</i> , 2019, 9, 18632.	1.6	18
287	Blood-brain barrier methodology and biology. , 1998, , 1-8.		18
288	CHO cell expression, long-term stability, and primate pharmacokinetics and brain uptake of an IgG-paroxonase fusion protein. <i>Biotechnology and Bioengineering</i> , 2011, 108, 186-196.	1.7	17

#	ARTICLE	IF	CITATIONS
289	Imaging Amyloid Plaque in Alzheimer's Disease Brain with a Biotinylated A $\beta$ 2 Peptide Radiopharmaceutical Conjugated to an IgG-Avidin Fusion Protein. <i>Bioconjugate Chemistry</i> , 2012, 23, 1318-1321.	1.8	17
290	Plasma Pharmacokinetics of High-Affinity Transferrin Receptor Antibody-Erythropoietin Fusion Protein is a Function of Effector Attenuation in Mice. <i>Molecular Pharmaceutics</i> , 2019, 16, 3534-3543.	2.3	17
291	Effects of Progesterone-Binding Globulin Versus a Progesterone Antiserum on Steroid Hormone Transport through the Blood-Brain Barrier*. <i>Endocrinology</i> , 1980, 106, 1137-1141.	1.4	16
292	Developmental changes in brain and serum binding of testosterone and in brain capillary uptake of testosterone-binding serum proteins in the rabbit. <i>Developmental Brain Research</i> , 1988, 38, 245-253.	2.1	16
293	Strategies for drug delivery through the blood-brain barrier. <i>Neurobiology of Aging</i> , 1989, 10, 636-637.	1.5	16
294	Very High Plasma Concentrations of a Monoclonal Antibody against the Human Insulin Receptor Are Produced by Subcutaneous Injection in the Rhesus Monkey. <i>Molecular Pharmaceutics</i> , 2016, 13, 3241-3246.	2.3	16
295	Lyoprotectant Optimization for the Freeze-Drying of Receptor-Targeted Trojan Horse Liposomes for Plasmid DNA Delivery. <i>Molecular Pharmaceutics</i> , 2020, 17, 2165-2174.	2.3	16
296	Role of intracellular calcium in regulation of brain endothelial permeability. , 1998, , 345-353.		15
297	Selective Lutheran Glycoprotein Gene Expression at the Blood-Brain Barrier in Normal Brain and in Human Brain Tumors. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 1096-1102.	2.4	15
298	Non-invasive gene targeting to the fetal brain after intravenous administration and transplacental transfer of plasmid DNA using PEGylated immunoliposomes. <i>Journal of Drug Targeting</i> , 2016, 24, 58-67.	2.1	15
299	The blood-brain barrier: Bottleneck in brain drug development. <i>Neurotherapeutics</i> , 2005, 2, 3-14.	2.1	15
300	Imaging Gene Expression in Regional Brain Ischemia In Vivo with a Targeted [ <sup>111</sup> In]-Antisense Radiopharmaceutical. <i>Molecular Imaging</i> , 2004, 3, 356-363.	0.7	15
301	Strategies for Drug Delivery through the Blood-Brain Barrier. , 1985, , 83-96.		14
302	Ultrastructural localization of blood-brain barrier-specific antibodies using immunogold-silver enhancement techniques. <i>Journal of Neuroscience Methods</i> , 1991, 37, 103-110.	1.3	14
303	Isolated brain capillaries: an in vitro model of blood-brain barrier research. , 1998, , 49-61.		14
304	Site-Directed Deletion of a 10-Nucleotide Domain of the 3'-Untranslated Region of the GLUT1 Glucose Transporter mRNA Eliminates Cytosolic Protein Binding in Human Brain Tumors and Induction of Reporter Gene Expression. <i>Journal of Neurochemistry</i> , 2002, 68, 2587-2592.	2.1	14
305	Human LAT1 single nucleotide polymorphism N230K does not alter phenylalanine transport. <i>Molecular Genetics and Metabolism</i> , 2004, 83, 306-311.	0.5	14
306	Biology of the blood-brain glucose transporter. , 1998, , 165-174.		14

#	ARTICLE	IF	CITATIONS
307	Kinetics of lactate transport into rat liver in vivo. <i>Metabolism: Clinical and Experimental</i> , 1990, 39, 374-377.	1.5	13
308	Decreases in brain protein synthesis elicited by moderate increases in plasma phenylalanine. <i>Biochemical and Biophysical Research Communications</i> , 1990, 168, 1177-1183.	1.0	13
309	Pharmacokinetic differences between <sup>111</sup> In- and <sup>125</sup> I-labeled cationized monoclonal antibody against $\beta$ 2-Amyloid in mouse and dog. <i>Drug Delivery</i> , 1995, 2, 128-135.	2.5	13
310	Hematologic safety of chronic brain-penetrating erythropoietin dosing in APP/PS1 mice. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 627-636.	1.8	13
311	Rat Blood-Brain Barrier Genomics. II. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002, , 1319-1326.	2.4	13
312	Blood-brain barrier genomics and the use of endogenous transporters to cause drug penetration into the brain. <i>Current Opinion in Drug Discovery &amp; Development</i> , 2003, 6, 683-91.	1.9	13
313	Acute and Chronic Dosing of a High-Affinity Rat/Mouse Chimeric Transferrin Receptor Antibody in Mice. <i>Pharmaceutics</i> , 2020, 12, 852.	2.0	12
314	Phenylalanine Transport at the Human Blood-Brain Barrier. , 1988, , 55-62.		12
315	New Directions in Blood-Brain Barrier Research.. <i>Annals of the New York Academy of Sciences</i> , 1988, 529, 50-60.	1.8	11
316	Blood-brain barrier ion transport. , 1998, , 207-213.		11
317	Developmental Regulation of the Rabbit Blood-Brain Barrier LAT1 Large Neutral Amino Acid Transporter mRNA and Protein. <i>Pediatric Research</i> , 2004, 55, 557-560.	1.1	11
318	Blood-brain barrier permeability measured with histochemistry. , 1998, , 113-121.		11
319	Brain microvasculature in multiple sclerosis. , 1998, , 386-400.		11
320	Reduction of testosterone availability to 5 $\alpha$ -reductase by human sex hormone-binding globulin in the rat ventral prostate gland in vivo. <i>Prostate</i> , 1990, 17, 281-291.	1.2	10
321	Targeting of an Anti-CR3 (CD11b/CD18) Monoclonal Antibody to Spleen But Not Brain, In Vivo in Mice. <i>Journal of Drug Targeting</i> , 1995, 3, 9-14.	2.1	10
322	Amplification of gene expression using both 5' and 3'-untranslated regions of GLUT1 glucose transporter mRNA. <i>Molecular Brain Research</i> , 1999, 63, 371-374.	2.5	10
323	Brain microvessel endothelial cell culture systems. , 1998, , 86-93.		9
324	Blood-brain barrier transport of drugs. , 1998, , 238-248.		9

#	ARTICLE	IF	CITATIONS
325	Physiologic-based strategies for protein drug delivery to the brain. <i>Journal of Controlled Release</i> , 1996, 39, 281-286.	4.8	8
326	The 5' Untranslated Region of GLUT1 Glucose Transporter mRNA Causes Differential Regulation of the Translational Rate in Plant and Animal Systems. <i>Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology</i> , 1997, 118, 309-312.	0.7	8
327	Treatment of Large Solid Tumors in Mice with Daunomycin-Loaded Sterically Stabilized Liposomes. <i>Drug Delivery</i> , 1998, 5, 207-212.	2.5	8
328	The blood-CSF barrier and the choroid plexus. , 1998, , 251-258.		8
329	Arachnoid membrane, subarachnoid CSF and pia glia. , 1998, , 259-269.		8
330	Circumventricular organs of the brain. , 1998, , 270-276.		8
331	Red cell phenylalanine is not available for transport through the blood-brain barrier. <i>Neurochemical Research</i> , 1990, 15, 769-772.	1.6	7
332	Transport in the developing brain. , 1998, , 277-290.		7
333	Isolation and behavior of plasma membrane vesicles made from cerebral capillary endothelial cells. , 1998, , 62-70.		7
334	Molecular dissection of tight junctions: occludin and ZO-1. , 1998, , 322-329.		6
335	The pathophysiology of blood-brain barrier dysfunction due to traumatic brain injury. , 1998, , 441-453.		6
336	Transport of small molecules through the blood-brain barrier: biology and methodology.. <i>Advanced Drug Delivery Reviews</i> , 1995, 15, 5-36.	6.6	6
337	Tissue culture of brain endothelial cells - induction of blood-brain barrier properties by brain factors. , 1998, , 79-85.		5
338	Preclinical studies of a brain penetrating IgG Trojan horse-arylsulfatase fusion protein in the metachromatic leukodystrophy mouse. <i>Molecular Genetics and Metabolism</i> , 2019, 126, S77.	0.5	5
339	Intracerebral microdialysis. , 1998, , 94-112.		5
340	Molecular biology of brain capillaries. , 1998, , 151-162.		5
341	P-glycoprotein, a guardian of the brain. , 1998, , 198-206.		5
342	Cerebral amyloid angiopathy. , 1998, , 379-385.		5

#	ARTICLE	IF	CITATIONS
343	Development of Brain Efflux Index (BEI) method and its application to the blood-brain barrier efflux transport study. , 1998, , 24-31.		4
344	HIV infection and the blood-brain barrier. , 1998, , 419-426.		4
345	Imaging Gene Expression in Regional Brain Ischemia in Vivo with a Targeted [ 111 In]-Antisense Radiopharmaceutical. Molecular Imaging, 2004, 3, 153535002004041.	0.7	4
346	Eliminating Fc N-Linked Glycosylation and Its Impact on Dosing Consideration for a Transferrin Receptor Antibody-Erythropoietin Fusion Protein in Mice. Molecular Pharmaceutics, 2020, 17, 2831-2839.	2.3	4
347	Steroid Hormone Transport through Blood-brain Barrier: Methods and Concepts. Methods in Neurosciences, 1994, 22, 3-22.	0.5	4
348	The blood-brain barrier in brain tumours. , 1998, , 434-440.		4
349	Localization of Blood-Brain Barrier-Specific Antibodies with Immunogold-Silver Enhancement. Journal of Histotechnology, 1993, 16, 249-257.	0.2	3
350	Drug transport across the blood-brain barrier: In Vitro and In Vivo techniques. Drug Delivery, 1998, 5, 153-153.	2.5	3
351	The carotid artery single injection technique. , 1998, , 11-23.		3
352	Blood-brain barrier and monoamines, revisited. , 1998, , 362-376.		3
353	Neuroprotection in stroke: is it time to consider large-molecule drugs?. Drug Discovery Today, 2001, 6, 751-753.	3.2	3
354	Brain Capillary Endothelial Transport of Insulin. , 1992, , 347-362.		3
355	Measuring cerebral capillary permeability-surface area products by quantitative autoradiography. , 1998, , 122-132.		3
356	Ion channels in endothelial cells. , 1998, , 214-220.		3
357	Microvascular pathology in cerebrovascular ischemia. , 1998, , 409-418.		3
358	Preface: Overview of brain drug delivery.. Advanced Drug Delivery Reviews, 1995, 15, 1-3.	6.6	3
359	Matters Arising. Journal of Neurochemistry, 1982, 39, 1774-1776.	2.1	2
360	Predominant Low-Molecular-Weight Proteins in Isolated Brain Capillaries Are Histones. Journal of Neurochemistry, 1989, 53, 1014-1018.	2.1	2

#	ARTICLE	IF	CITATIONS
361	Formulation of therapeutic synthetic polymers for drug and gene delivery $\frac{1}{4}$ . Drug Discovery Today, 2002, 7, 1120-1121.	3.2	2
362	Imaging gene expression in the brain with peptide nucleic acid (PNA) antisense radiopharmaceuticals and drug targeting technology. International Journal of Peptide Research and Therapeutics, 2003, 10, 169-190.	0.9	2
363	Safety and clinical efficacy of ACT-181, a brain penetrating human insulin receptor antibody-iduronidase fusion protein, in a 26-week study with pediatric patients with mucopolysaccharidosis type I. Molecular Genetics and Metabolism, 2018, 123, S54.	0.5	2
364	Blood-Brain Barrier Transport Mechanisms. , 1997, , 21-25.		2
365	Patch clamp techniques with isolated brain microvessel membranes. , 1998, , 71-78.		2
366	Measurement of blood-brain barrier in humans using indicator diffusion. , 1998, , 133-139.		2
367	Regulation of brain endothelial cell tight junction permeability. , 1998, , 293-300.		2
368	Nitric oxide and endothelin at the blood-brain barrier. , 1998, , 338-344.		2
369	Vector-mediated peptide drug delivery to the brain.. Advanced Drug Delivery Reviews, 1995, 15, 109-146.	6.6	2
370	The effects of membrane permeability and binding by human serum proteins on steroid influx into the rabbit uterus. American Journal of Obstetrics and Gynecology, 1987, 157, 1543-1549.	0.7	1
371	Triiodothyronine bound to red blood cells is not available for transport through the blood-brain barrier. Neurochemical Research, 1989, 14, 657-659.	1.6	1
372	Interactions of lipoproteins with the blood-brain barrier. , 1998, , 221-226.		1
373	Cytokines and the blood-brain barrier. , 1998, , 354-361.		1
374	<i>In situ</i> brain perfusion. , 1998, , 32-40.		1
375	Imaging Gene Expression in the Brain with Peptide Nucleic Acid (PNA) Antisense Radiopharmaceuticals and Drug Targeting Technology. , 2006, , 38-60.		1
376	P3057: THERAPEUTIC EFFECTS OF A BRAIN PENETRATING BISPECIFIC ERYTHROPOIETIN-TRANSFERRIN RECEPTOR ANTIBODY FUSION PROTEIN IN THE APP/PS1 MOUSE MODEL OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1086.	0.4	1
377	Platform technology for treatment of the brain in lysosomal disorders: Application to Niemann-Pick disease type A. Molecular Genetics and Metabolism, 2019, 126, S95-S96.	0.5	1
378	Molecular Regulation of Blood-Brain Barrier GLUT1 Glucose Transporter. , 1995, , 81-88.		1

#	ARTICLE	IF	CITATIONS
379	Blood-Brain Barrier Transport for RNAi. , 2009, , 255-273.		1
380	Receptor-mediated peptide transport through the blood-brain barrier. , 1988, , 593-595.		1
381	Measurement of bloodâ€‘brain permeability in humans with positron emission tomography. , 1998, , 140-146.		1
382	Glucose transporters in mammalian brain development. , 1998, , 175-187.		1
383	Chemotherapy and chemosensitization. , 1998, , 301-307.		1
384	Hemostasis and the bloodâ€‘brain barrier. , 1998, , 401-408.		1
385	Brain microvessel antigens. , 1998, , 314-321.		1
386	S1-01-01: Blood-brain barrier from physiology to therapeutics. , 2015, 11, P114-P114.		0
387	[O4â€‘06â€‘04]: PROTECTIVE EFFECTS OF A BRAINâ€‘PENETRATING BIOLOGIC TNFâ€‘ALPHA INHIBITOR IN A MOUSE MODEL OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1242.	0.4	0
388	Platform technology for treatment of the brain in lysosomal disorders. Molecular Genetics and Metabolism, 2018, 123, S77.	0.5	0
389	Platform technology for treatment of the brain in lysosomal disorders: Application to Tay-Sachs disease. Molecular Genetics and Metabolism, 2019, 126, S32.	0.5	0
390	Platform technology for treatment of the brain in lysosomal diseases: Application to NCL1 Batten disease. Molecular Genetics and Metabolism, 2019, 126, S114-S115.	0.5	0
391	Lipid composition of brain microvessels. , 1998, , 308-313.		0
392	Magnetic resonance imaging of bloodâ€‘brain barrier permeability. , 1998, , 147-150.		0
393	Intravenous injection/pharmacokinetics. , 1998, , 41-48.		0
394	Fatty acid and lipid intermediate transport. , 1998, , 227-237.		0
395	Phosphatidylinositol pathways. , 1998, , 330-337.		0
396	Bloodâ€‘Brain Barrier Targeting of Therapeutic Lysosomal Enzymes. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , 41-62.	0.2	0

#	ARTICLE	IF	CITATIONS
397	Imaging gene expression in the brain with peptide nucleic acid (PNA) antisense radiopharmaceuticals and drug targeting technology. <i>International Journal of Peptide Research and Therapeutics</i> , 2005, 10, 169-190.	0.9	0
398	Imaging gene expression in the brain with peptide nucleic acid (PNA) antisense radiopharmaceuticals and drug targeting technology. <i>International Journal of Peptide Research and Therapeutics</i> , 2003, 10, 169-190.	0.1	0
399	Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy. <i>Neurotherapeutics</i> , 2005, 2, 129-138.	2.1	0